



**New Hampshire Medicaid Fee-for-Service Program
Prior Authorization Drug Approval Form**

Duchenne Muscular Dystrophy Agents

DATE OF MEDICATION REQUEST: / /

SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

				-					-						
--	--	--	--	---	--	--	--	--	---	--	--	--	--	--	--

GENDER: Male Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

SECTION II: PRESCRIBER INFORMATION

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

				-					-						
--	--	--	--	---	--	--	--	--	---	--	--	--	--	--	--

FAX NUMBER:

				-					-						
--	--	--	--	---	--	--	--	--	---	--	--	--	--	--	--

SECTION III: CLINICAL HISTORY

- Does the patient have a confirmed diagnosis of Duchenne Muscular Dystrophy? Yes No
- Exondys 51 only:** Has genetic testing been completed to identify a mutation on the DMD gene amenable to exon 51 skipping? Yes No
- Viltepto or Vyondys 53 only:** Has genetic testing been completed to identify a mutation on the DMD gene amenable to exon 53 skipping? Yes No
- Amondys 45 only:** Has genetic testing been completed to identify a mutation on the DMD gene amenable to exon 45 skipping? Yes No

(Form continued on next page.)



**New Hampshire Medicaid Fee-for-Service Program
Prior Authorization Drug Approval Form**

Duchenne Muscular Dystrophy Agents

DATE OF MEDICATION REQUEST: / /

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SECTION III: CLINICAL HISTORY (CONTINUED)

5. Is the patient on a stable dose of corticosteroids? Yes No

a. If **yes** to question 5, list the medication and start date:

b. If **no** to question 5, list the intolerance or contraindication:

6. Does the patient continue to have voluntary motor function? Yes No

7. Is the patient receiving physical and/or occupational therapy? Yes No

8. **Amondys 45, Vyondys 53, and Viltepso® only:**

a. Prior to initiating therapy, will serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio be measured? Yes No

b. Will the urine dipstick and serum cystatin C be measured monthly and urine protein-to-creatinine ratio by assessed every 3 months during therapy? Yes No

9. **Viltepso® only:** Does the patient have symptomatic cardiomyopathy? Yes No

10. Has a baseline assessment been completed with at least one of the following? Yes No

- Dystrophin Level
- 6-minute walk test (6MWT) or other timed test
- Upper limb module (ULM) score
- North Star Ambulatory Assessment (NSAA)
- Forced Vital Capacity (FVC)% predicted

(Form continued on the next page.)



**New Hampshire Medicaid Fee-for-Service Program
Prior Authorization Drug Approval Form**

Duchenne Muscular Dystrophy Agents

DATE OF MEDICATION REQUEST: / /

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SECTION III: CLINICAL HISTORY (CONTINUED)

11. **For renewals (every 120 days):** Patient must demonstrate stability, improvement, or slowed rate of progression in one of the above assessments.

Renewal assessment results:

Please provide any additional information that would help in the decision-making process. **If additional space is needed, please use a separate sheet.**

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: _____ **DATE:** _____

Facility where infusion is to be provided: _____

Medicaid provider number of facility: _____